NO20052059L - Terapier for kronisk inflammatorisk demyeliniserende polynevropati ved anvendelse av interferon-beta. - Google Patents

Terapier for kronisk inflammatorisk demyeliniserende polynevropati ved anvendelse av interferon-beta.

Info

Publication number
NO20052059L
NO20052059L NO20052059A NO20052059A NO20052059L NO 20052059 L NO20052059 L NO 20052059L NO 20052059 A NO20052059 A NO 20052059A NO 20052059 A NO20052059 A NO 20052059A NO 20052059 L NO20052059 L NO 20052059L
Authority
NO
Norway
Prior art keywords
interferon
therapies
beta
chronic inflammatory
inflammatory demyelinating
Prior art date
Application number
NO20052059A
Other languages
English (en)
Norwegian (no)
Other versions
NO20052059D0 (no
Inventor
Alfred Sandrock
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of NO20052059D0 publication Critical patent/NO20052059D0/no
Publication of NO20052059L publication Critical patent/NO20052059L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20052059A 2002-09-27 2005-04-27 Terapier for kronisk inflammatorisk demyeliniserende polynevropati ved anvendelse av interferon-beta. NO20052059L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41430702P 2002-09-27 2002-09-27
PCT/US2003/030532 WO2004028472A2 (en) 2002-09-27 2003-09-26 THERAPIES FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY USING INTERFERON-β

Publications (2)

Publication Number Publication Date
NO20052059D0 NO20052059D0 (no) 2005-04-27
NO20052059L true NO20052059L (no) 2005-06-27

Family

ID=32043377

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052059A NO20052059L (no) 2002-09-27 2005-04-27 Terapier for kronisk inflammatorisk demyeliniserende polynevropati ved anvendelse av interferon-beta.

Country Status (21)

Country Link
US (2) US20060182715A1 (pl)
EP (1) EP1575531B9 (pl)
JP (3) JP2006513990A (pl)
KR (1) KR20050059195A (pl)
CN (2) CN102038938A (pl)
AT (1) ATE520412T1 (pl)
AU (1) AU2003277006C1 (pl)
BR (1) BR0314548A (pl)
CA (1) CA2500189A1 (pl)
DK (1) DK1575531T3 (pl)
EA (1) EA009289B1 (pl)
GE (1) GEP20094699B (pl)
IS (1) IS7746A (pl)
MX (1) MXPA05003243A (pl)
NO (1) NO20052059L (pl)
NZ (1) NZ565990A (pl)
PL (1) PL377612A1 (pl)
RS (1) RS20050255A (pl)
UA (1) UA86749C2 (pl)
WO (1) WO2004028472A2 (pl)
ZA (1) ZA200502416B (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1575531T3 (da) * 2002-09-27 2011-11-21 Biogen Idec Inc Terapier for kronisk inflammatorisk demyeliniserende polyneuropati under anvendelse af interferon-beta
TW200633718A (en) * 2004-12-16 2006-10-01 Applied Research Systems Treatment of hepatitis c in the asian population
WO2008130382A2 (en) 2006-10-31 2008-10-30 East Carolina University Fusion proteins comprising an anti -inflammatory cytokine and an antigen for treatment of immune disorders
WO2010117848A1 (en) 2009-03-31 2010-10-14 East Carolina University Cytokines and neuroantigens for treatment of immune disorders
IN2014CN02982A (pl) * 2011-10-01 2015-07-03 Glytech Inc
GB201212878D0 (en) 2012-07-20 2012-09-05 Pike Justin Authentication method and system
EP3072513A1 (en) 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis
GB201520741D0 (en) 2015-05-27 2016-01-06 Mypinpad Ltd And Licentia Group Ltd Authentication methods and systems
WO2020009437A1 (ko) * 2018-07-04 2020-01-09 서울대학교산학협력단 신경손상의 면역세포치료
GB201916441D0 (en) 2019-11-12 2019-12-25 Mypinpad Ltd Computer-implemented system and method
WO2026010306A1 (ko) * 2024-07-02 2026-01-08 주식회사 카인사이언스 탈수초 질환 치료를 위한 펩타이드 및 ivig의 병용 요법
KR20260005781A (ko) * 2024-07-02 2026-01-12 주식회사 카인사이언스 만성 염증성 탈수초 다발신경병증에 대한 펩타이드의 투여요법

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3572982D1 (en) * 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
ZA878295B (en) * 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease
DE3712564A1 (de) * 1987-04-14 1988-11-24 Bioferon Biochem Substanz Verfahren zur konstruktion einer animalen zellinie fuer die herstellung von humanem interferon-beta
DE4128319A1 (de) * 1991-08-27 1993-03-04 Bioferon Biochem Substanz Neues rekombinantes human-ifn-beta, verfahren zu dessen herstellung und dieses enthaltende pharmazeutische zubereitungen
US5545723A (en) * 1994-03-15 1996-08-13 Biogen Inc. Muteins of IFN-β
IL113280A (en) * 1994-04-12 2004-12-15 Res Dev Foundation A preparation for the treatment of self-immunization diseases with the help of interferon of one type
ZA952797B (en) * 1994-04-12 1996-10-07 Res Dev Foundation Method of treating auto-immune diseases using type one interferons
TW403653B (en) * 1995-12-25 2000-09-01 Otsuka Pharma Co Ltd Dry compositions
AU766190B2 (en) * 1998-10-16 2003-10-09 Biogen Idec Ma Inc. Interferon-beta fusion proteins and uses
DK1656952T3 (da) * 1998-10-16 2014-01-20 Biogen Idec Inc Polyalkylenglycolkonjugater af interferon beta-1A og anvendelser deraf
US6419934B1 (en) * 1999-02-24 2002-07-16 Edward L. Tobinick TNF modulators for treating neurological disorders associated with viral infection
WO2000050620A2 (en) * 1999-02-26 2000-08-31 Human Genome Sciences, Inc. Human endokine alpha and methods of use
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
WO2002036628A2 (en) * 2000-11-02 2002-05-10 Maxygen Aps New multimeric interferon beta polypeptides
EP1366075B1 (en) * 2001-02-27 2009-05-27 Maxygen Aps New interferon beta-like molecules
US20030091544A1 (en) * 2001-03-13 2003-05-15 Vical Incorporated Interferon-Beta polynucleotide therapy for autoimmune and inflammatory diseases
DK1575531T3 (da) * 2002-09-27 2011-11-21 Biogen Idec Inc Terapier for kronisk inflammatorisk demyeliniserende polyneuropati under anvendelse af interferon-beta

Also Published As

Publication number Publication date
AU2003277006B2 (en) 2009-09-10
EA009289B1 (ru) 2007-12-28
IS7746A (is) 2005-03-15
CN1802170A (zh) 2006-07-12
ZA200502416B (en) 2005-10-20
BR0314548A (pt) 2005-08-09
EA200500545A2 (ru) 2005-08-25
RS20050255A (sr) 2007-08-03
GEP20094699B (en) 2009-06-10
JP2006513990A (ja) 2006-04-27
NZ565990A (en) 2009-10-30
NO20052059D0 (no) 2005-04-27
US20120058083A1 (en) 2012-03-08
PL377612A1 (pl) 2006-02-06
EP1575531A4 (en) 2008-01-23
CN102038938A (zh) 2011-05-04
WO2004028472A2 (en) 2004-04-08
EP1575531B1 (en) 2011-08-17
JP2011132248A (ja) 2011-07-07
DK1575531T3 (da) 2011-11-21
EA200500545A3 (ru) 2007-04-27
MXPA05003243A (es) 2005-09-12
ATE520412T1 (de) 2011-09-15
WO2004028472A3 (en) 2006-01-19
AU2003277006A1 (en) 2004-04-19
US20060182715A1 (en) 2006-08-17
AU2003277006C1 (en) 2010-04-01
EP1575531B9 (en) 2012-02-22
CA2500189A1 (en) 2004-04-08
JP2007039463A (ja) 2007-02-15
EP1575531A2 (en) 2005-09-21
KR20050059195A (ko) 2005-06-17
UA86749C2 (en) 2009-05-25

Similar Documents

Publication Publication Date Title
EA200500218A1 (ru) ЛЕЧЕНИЕ ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТИ С ПРИМЕНЕНИЕМ ИНТЕРФЕРОНА-β
NO20052923L (no) Fusjonerte bicykliske nitrogeninneholdende heteroringer
DK1539166T3 (da) Farmaceutiske sammensætninger indeholdende dextromethorphan og quinidin til behandling af neurologiske sygdomme
LTPA2017009I1 (lt) Brutono tirozinkinazės inhibitoriai
ATE304017T1 (de) Oxazolylpyrazol-derivate als kinase-inhibitoren
NO20050795L (no) Forbindelser, blandinger og fremgangsmater for utnyttelse av samme
NO20052059D0 (no) Terapier for kronisk inflammatorisk demyeliniserende polynevropati ved anvendelse av interferon-beta.
BRPI0414435A (pt) métodos e reagentes para o tratamento de distúrbios imunoinflamatórios
NO20015991L (no) Bicykliske polyaminosyre-metallkomplekser, fremgangsmåter for fremstilling av disse og deres anvendelse ved medisinsk avbildning
NO20050497L (no) Anvendelse av CETP inhibitorer og eventuelt HMG COA reduserbare inhibitorer og/eller antihypertensiva
ATE411022T1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
NO20070073L (no) Pyrazolderivater, preparater inneholdende disse og metoder for anvendelse derav
DE60315479D1 (de) Pyrimidinamid derivate und deren verwendung
EA200500764A1 (ru) Фармацевтические композиции и лекарственные формы для трансбуккальной и сублингвальной доставки тизанидина и способы введения тизанидина сублингвально или трансбуккально
WO2007120156A3 (en) Animal models of long qt syndrome and uses thereof
MY140194A (en) Novel fusidic acid derivatives
EP1364652A4 (en) CURE FOR LUNG CANCER
CY1105117T1 (el) Θepαπειες για τη χρονια νεφρικη ανεπαρκεια χρησιμοποιωντας ανταγωνιστες των ενσωματινων
ATE544453T1 (de) Kombinationstherapien mit l-fmau zur behandlung von hepatitis-b-virus-infektionen
MXPA05002477A (es) Asialo-interferones y el tratamiento de cancer de higado.
TW200510447A (en) Novel fusidic acid derivatives

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application